Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Radioembolization with Intra-arterial Angiotensin II in Liver Cancer
2025-521870-33-00Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Angiotensin II in liver cancer, hepatocellular carcinoma (HCC) and hepatic metastasis, sponsored by University Medical Center Utrecht. Primary endpoint: Tumor-to-normal liver ratio improvement factor. Planned start Aug 2025; status: authorised.
02
Drugs
Angiotensin II
03
Conditions
liver cancerhepatocellular carcinoma (HCC)hepatic metastasis
Beyond the preview
Go deeper on 2025-521870-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521870-33-00.